Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies

Vaccine

Volumn 25, Issue 21, 2007, Pages 4213-4222

  Weyer, Jacqueline ^a   Rupprecht, Charles E ^b   Mans, Janet ^c   Viljoen, Gerrit J ^c   Nel, Louis H ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c ONDERSTEPOORT VETERINARY INSTITUTE   (South Africa)

Author keywords

Modified vaccinia virus Ankara; Oral vaccine; Rabies vaccine

Indexed keywords

MODIFIED VACCINIA VIRUS ANKARA VACCINE; RABIES VACCINE; RABIES VIRUS GLYCOPROTEIN; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA VIRUS VECTOR; UNCLASSIFIED DRUG; VACCINIA COPENHAGEN VIRUS VACCINE; VACCINIA COPENHAGEN VIRUS VECTOR; VACCINIA VACCINE; VACCINIA WESTERN RESERVE VACCINE; VACCINIA WESTERN RESERVE VIRUS VECTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL PROCEDURES; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABIES; RABIES VIRUS GLYCOPROTEIN GENE;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; CHICKENS; CRICETINAE; DOGS; FEMALE; GLYCOPROTEINS; IMMUNOLOGIC MEMORY; MESOCRICETUS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NEUTRALIZATION TESTS; RABIES; RABIES VACCINES; RABIES VIRUS; RACCOONS; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 34247381211     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.02.084     Document Type: Article

References (71)

1. Tordo N., Benmansour A., Calisher C., Dietzgen R.G., Fang R.-X., Jackson A.O., et al. Lyssaviruses. In: Fauquet C.M., Mayo M.A., Maniloff J., Desselberger U., and Ball L.A. (Eds). Virus taxonomy: the classification and nomenclature of viruses. The 8th report of the International Committee on Taxonomy of Viruses (2005), Oxford Academic, San Diego 623-629
2. Willoughby R.E., Tieves K.S., Hoffman G.M., Ghanayem N.S., Amlie-Lefond C.M., Schwabe M.J., et al. Survival after treatment of rabies with induction of coma. N Engl J Med 352 (2005) 2508-2514
3. Anonymous. World Survey for Rabies No 35 for the year 1999. WHO/CD/CSR/EPH/2002.10. World Health Organization, Geneva, 2002.
4. Anonymous. World Health Organization Expert Consultation on Rabies: First report. World Health Organization Technical report series 931. World Health Organization, Geneva, 2005, pp. 15-19.
5. Rupprecht C.E., and Gibbons R.V. Prophylaxis against rabies. N Engl J Med 351 (2004) 2626-2635
6. Debbie J.G. Rabies control of terrestrial wildlife by population reduction. In: Baer G.M. (Ed). The Natural History of Rabies. 2nd ed. (1991), CRC Press, Boca Raton & Ann Arbor & Boston 477-484
7. Anonymous. Field application of oral rabies vaccines for dogs: report of a WHO consultation organized in collaboration with the Office International des Epizooties (OIE). World Health Organization, Geneva, 1998; WHO/EMC/ZDI/98, 15.
8. Rupprecht C.E., Hanlon C.A., Blanton J., Manangan J., Morrill P., Murphy S., et al. Oral vaccination of dogs with recombinant rabies virus vaccines. Vir Res 111 1 (2005) 101-105
9. Kieny M.-P., Lathe R., Drillien R., Spehner D., Shory S., Schmitt D., et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 312 (1984) 163-166
10. Wiktor T.J., MacFarlan R.I., Reagen K.J., Dietschold B., Curtis P.J., Wunner W.H., et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein recombinant virus vaccine. Proc Natl Acad Sci USA 81 (1984) 7194-7198
11. Rupprecht C.E., and Kieny M.-P. Development of a vaccinia-rabies glycoprotein recombinant virus vaccine. In: Campbell J.B., and Charlton K.M. (Eds). Rabies (1988), Kluwer Academic Publishers, Boston 335-364
12. Krebs J.W., Mandel E.J., Swerdlow D.L., and Rupprecht C.E. Rabies surveillance in the United States during 2004. JAVMA 227 12 (2005) 1912-1925
13. Schumacher C.L., Coulon P., Lafay F., Bénéjean J., Aubert M.F.A., Barrat J., et al. SAG-2 oral rabies vaccine. OJVR 60 (1993) 459-462
14. Redfield R.R., Wright D.C., James W.D., Jones T.S., Brown C., and Burke D.S. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316 11 (1987) 673-676
15. Rupprecht C.E., Blass L., Smith K., Orciari L.A., Niezgoda M., Whitfield S.G., et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med 345 8 (2001) 582-586
16. Smith G.L., Mackett M., and Moss B. Infectious vaccinia virus recombinants that express hepatitis B surface antigen. Nature 302 (1983) 490
17. Perkus M.E., Piccini A., Lipinskas B.R., and Paoletti E. Recombinant vaccinia virus: immunization against multiple pathogens. Science 229 (1985) 981-984
18. Andrew M.E., Coupar B.E.H., and Boyle D.B. Immunogenicity and antigen presentation. In: Binns M.M., and Smith G.L. (Eds). Recombinant poxviruses (1992), CRC Press, Boca Raton 207-234
19. Zavala F., Rodrigues M., Rodrigues D., Rodrigues J., Nussenzweig R., and Esteban M. A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8+ T cells. Virology 280 (2001) 155-159
20. Pastoret P.-P., and Vanderplasschen A. Poxviruses as vaccine vectors. Comparative Immunology. Microbiol Infect Dis 26 (2003) 343-355
21. Dudek T., and Knipe D.M. Replication-defective viruses as vaccines and vaccine vectors. Virology 344 (2006) 230-239
22. Fekadu M., Shaddock J.H., Sumner J.W., Sanderlin D.W., Knight J.C., Esposito J.J., et al. Oral vaccination of skunks with raccoon poxvirus recombinants expressing the rabies glycoprotein or the nucleoprotein. J Wild Dis 27 4 (1991) 681-684
23. Hu L., Ngicabe C., Trimarchi C.V., Esposito J.J., and Scot F.W. Raccoon poxvirus live recombinant feline panleukopenia virus VP2 and rabies virus glycoprotein bivalent vaccine. Vaccine 15 12-13 (1997) 1466-1472
24. Fries L.F., Tartaglia J., Taylor J., Kauffman E.K., Meignier B., Paoletti E., et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 14 5 (1996) 428-434
25. Sutter G., and Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets-Infect Disord 3 (2003) 263-271
26. Drexler I., Staib C., and Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?. Curr Opin Biotechnol 15 (2004) 1-7
27. Hanke T., McMicheal A.J., Samuel R.V., Powell L.A.J., McLoughlin L., Crome S.J., et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA and modified vaccinia virus Ankara (MVA)-based HIV vaccine for Kenya. Vaccine 21 (2002) 108-114
28. Moorthy V.S., McConkey S., Robert M., Gothard P., Arulanantham N., Degano P., et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteer. Vaccine 21 (2003) 1995-2000
29. Van Rompay K.K.A., Freenier J.L., Cole K.S., Earl P., Moss B., Stechbeck J.D., et al. Immunization of newborn rhesus macaques with simian immunodefiency virus (SIV) vaccine prolongs survival after oral challenge with virulent SIVmac251. J Virol 77 1 (2003) 179-190
30. Stittelaar K.J., Kuiken T., de Swart R.L., Van Amerongen G., Vos H.M., Niesters H.G.M., et al. Osterhaus ADME. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19 (2001) 3700-3709
31. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72 (1991) 1031-1308
32. Antoine G., Scheiflinger F., Dorner F., and Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244 (1998) 365-396
33. Blanchard T.J., Alcami A., Andrea P., and Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79 (1998) 1159-1167
34. Wyatt L.S., Carroll M.W., Czerny C.P., Merchilinsky M., Sisler J.R., and Moss B. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology 251 (1998) 334-342
35. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89 (1992) 10847-10851
36. Carroll M.W., and Moss B. Host range and cytopathogenicity of highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238 (1997) 198-211
37. Drexler I., Heller K., Wahren B., Erfle V., and Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 49 (1998) 347-352
38. Ramίrez J.C., Gherardi M.M., and Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74 2 (2000) 923-933
39. Minev B.R., Chavez F.L., and Mitchell M.S. Cancer vaccines: novel approaches and new promise. Pharmacol Ther 81 2 (1999) 121-139
40. Bonnet M.C., Tartaglia J., Verdier F., Kourlisky P., Lindberg A., Klen M., et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 74 (2000) 11-25
41. Carroll M.W., Overwijk W.W., Chamberlian R.S., Rosenberg S.A., Moss B., and Restifo N.P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15 4 (1997) 387-394
42. Hanke T., Blanchard T.J., Schneider J., Hannan C.M., Becker M., Gilbert S.C., et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16 5 (1998) 439-445
43. Gomez C.E., Rodriques D., Rodriquez J.R., Abaitua F., Duarte C., and Esteban M. Enhanced CD8+ response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector. Vaccine 20 (2002) 961-971
44. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4 4 (1998) 397-402
45. González-Aseguinolaza G., Nakaya Y., Molano A., Dy E., Esteban M., Rodrigues D., et al. Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia virus Ankara expressing a CD8+ T cell epitope derived from the circumsporozoite protein of Plasmodium yeoli. J Virol 77 21 (2003) 11859-11866
46. Dégano P., Schneider J., Hannan C.M., Gilbert S.C., and Hill A.V.S. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 18 (2000) 623-632
47. Ramshaw I.A., and Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 21 4 (2000) 163-165
48. Woodland D.L. Jump-start the immune system: prime-boosting comes of age. Trends Immunol 25 2 (2004) 98-104
49. Freshney R.I. The culture of animal cells: a manual of basic technique. 3rd ed. (1994), Wiley Liss, New York pp. 127-147
50. Kaaden O.R., Lange S., and Stiburek B. Establishment and characterization of chicken embryo fibroblast clone LSCC-H32. In Vitro 18 10 (1982) 827-834
51. Sambrook J, Russell DW. Molecular cloning: a laboratory manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 1.31-1.38.
52. Staib C., Löwel M., Erfle V., and Sutter G. Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques 34 4 (2003) 694-700
53. Staib C., Drexler M., Ohlmann S., Wintersperger S., Erfle V., and Sutter G. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 28 (2000) 1137-1148
54. Wallace D.B., and Viljoen G.J. Immune responses to recombinants of South African vaccine strain of lumpy skin disease generated by using thymidine kinase gene insertion. Vaccine 23 23 (2003) 3061-3067
55. Weyer J. Immune responses to recombinant poxviruses expressing lyssavirus glycoprotein genes. University of Pretoria, Ph.D. thesis, 2006, p. 88.
56. Moss B, Earl PL. Expression of proteins in mammalian cells using vaccinia viral vectors. In: Current Protocols in Molecular Biology. John Wiley and Sons, p. 16.15.1-16.15.5.
57. Byrd CM, Hruby DE. Construction of recombinant vaccinia virus. in: Isaacs, SN., (Ed.), Vaccinia virus and poxvirology, Humana Press, Totowa New Jersey, p31-40.
58. Esposito J., Condit R., and Obijeski J. The preparation of orthopoxvirus DNA. J Virol Meth 2 (1981) 175-179
59. Pasamontes L., Gubser J., Wittek R., and Viljoen G.J. Direct identification of recombinant virus plaques by PCR. J Virol Meth 35 (1991) 137-141
60. Dean D.J., Abelseth M.K., and Atanasiu P. The fluorescent antibody test. In: Meslin F.-X., Kaplan M.M., and Koprowski H. (Eds). Laboratory techniques in rabies. 4th ed. (1996), World Health Organization, Geneva 88-95
61. Lodmell D.L., Ewalt L.C., Parnell M.J., Rupprecht C.E., and Hanlon C.A. One-time intradermal DNA vaccination in ear pinnae one year prior to infection protects dogs against rabies. Vaccine 24 4 (2006) 412-416
62. Smith J.S., Yager P.A., and Baer G.M. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody. In: Meslin F.-X., Kaplan M.M., and Koprowski H. (Eds). Laboratory techniques in Rabies. 4th ed. (1996), World Health Organization, Geneva 181-192
63. Falkner F.G., and Moss B. Transient dominant selection of recombinant vaccinia viruses. J Virol 64 3 (1990) 108-111
64. Stittelaar K.J., Wyatt L.S., De Swart R.L., Vos H.W., Groen J., Van Amerongen G., et al. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol 74 9 (2000) 4236-4243
65. Bertley F.M.N., Kozlowski P.A., Wang S.-W., Chappelle J., Patel J., Sonuyi O., et al. Control of simian/human immunodeficiency virus viremia and disease progression after Il-2-augmented DNA-Modified Vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 172 6 (2004) 3745-3757
66. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78 8 (2004) 3930-3940
67. De Waal L., Wyatt L.S., Yu{combining double acute accent}ksel S., Van Amerongen G., Moss B., Niesters H.G.M., et al. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine 22 (2004) 923-926
68. Bender B.S., Rowe C.A., Taylor S.F., Wyatt L.S., Moss B., and Small P.A. Oral immunization with a replication deficient recombinant vaccinia virus protects mice against influenza. J Virol 70 (1996) 6418-6424
69. Gherardi M.M., and Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 86 11 (2005) 2925-2936
70. Belyakov I., Moss B., Strober W., and Berzofsky J.A. Mucosal vaccination overcomes barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci USA 96 (1999) 4512-4517
71. Lodmell D.L., Esposito J.J., and Ewalt L.C. Live vaccinia rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte deficient A/WySNJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals. Vaccine 22 (2004) 3329-3333